Skip to main content
Erschienen in: Osteoporosis International 3/2018

05.12.2017 | Original Article

Insights into the bisphosphonate holiday: a preliminary FTIRI study

verfasst von: A. L. Boskey, L. Spevak, Y. Ma, H. Wang, D. C. Bauer, D. M. Black, A. V. Schwartz

Erschienen in: Osteoporosis International | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Summary

Bone composition evaluated by FTIRI analysis of iliac crest biopsies from post-menopausal women treated with alendronate for 10 years, continuously or alendronate for 5 years, followed by a 5-year alendronate-holiday, only differed with the discontinued biopsies having increased cortical crystallinity and heterogeneity of acid phosphate substitution and decreased trabecular crystallinity heterogeneity.

Introduction

Bisphosphonates (BP) are the most commonly used and effective drugs to prevent fragility fractures; however, concerns exist that prolonged use may lead to adverse events. Recent recommendations suggest consideration of a BP “holiday” in individuals taking long-term BP therapy not at high risk of fracture. Data supporting or refuting this recommendation based on bone quality are limited. We hypothesized that a “holiday” of 5 years would cause no major bone compositional changes.

Methods

We analyzed the 31 available biopsies from the FLEX-Long-term Extension of FIT (Fracture Intervention Trial) using Fourier transform infrared imaging (FTIRI). Biopsies from two groups of post-menopausal women, a “Continuously treated group” (N = 16) receiving alendronate for ~ 10 years and a “Discontinued group” (N = 15), alendronate treated for 5 years taking no antiresorptive medication during the following 5 years. Iliac crest bone biopsies were provided at 10 years.

Results

Key FTIRI parameters, mineral-to-matrix ratio, carbonate-to-phosphate ratio, acid phosphate substitution, and collagen cross-link ratio as well as heterogeneity of these parameters were similar for Continuously treated and Discontinued groups in age-adjusted models. The Discontinued group had 2% greater cortical crystallinity (p = 0.01), 31% greater cortical acid phosphate heterogeneity (p = 0.02), and 24% lower trabecular crystallinity heterogeneity (p = 0.02).

Conclusions

Discontinuation of alendronate for 5 years did not affect key FTIRI parameters, supporting the hypothesis that discontinuation would have little impact on bone composition. Modest differences were observed in three parameters that are not likely to affect bone mechanical properties. These preliminary data suggest that a 5-year BP holiday is not harmful to bone composition.
Literatur
4.
Zurück zum Zitat Imbert LBA Effects of drugs on bone quality. Clin Rev Bone Mineral Metab 14:167–196 Imbert LBA Effects of drugs on bone quality. Clin Rev Bone Mineral Metab 14:167–196
12.
Zurück zum Zitat Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2005) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2005) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone
13.
Zurück zum Zitat LH X, Adams-Huet B, Poindexter JR, Maalouf NM (2016) Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. Osteoporos Int 27:1701–1708CrossRef LH X, Adams-Huet B, Poindexter JR, Maalouf NM (2016) Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. Osteoporos Int 27:1701–1708CrossRef
14.
Zurück zum Zitat Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31(1):16–35. https://doi.org/10.1002/jbmr.2708 CrossRefPubMedPubMedCentral Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31(1):16–35. https://​doi.​org/​10.​1002/​jbmr.​2708 CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat FDA drug safety communications: ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer FDA drug safety communications: ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer
19.
Zurück zum Zitat Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P, Phipps R, Klaushofer K (2006) Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res 21(7):1106–1112. https://doi.org/10.1359/jbmr.060401 CrossRefPubMed Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P, Phipps R, Klaushofer K (2006) Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res 21(7):1106–1112. https://​doi.​org/​10.​1359/​jbmr.​060401 CrossRefPubMed
20.
Zurück zum Zitat Roschger P, Lombardi A, Misof BM, Maier G, Fratzl-Zelman N, Fratzl P, Klaushofer K (2010) Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX). J Bone Miner Res 25(1):48–55. https://doi.org/10.1359/jbmr.090702 CrossRefPubMed Roschger P, Lombardi A, Misof BM, Maier G, Fratzl-Zelman N, Fratzl P, Klaushofer K (2010) Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX). J Bone Miner Res 25(1):48–55. https://​doi.​org/​10.​1359/​jbmr.​090702 CrossRefPubMed
21.
Zurück zum Zitat Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP (2010) Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid. J Bone Miner Res 26:12–18CrossRef Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP (2010) Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid. J Bone Miner Res 26:12–18CrossRef
25.
Zurück zum Zitat Hamrick MW, Skedros JG, Pennington C, McNeil PL (2006) Increased osteogenic response to exercise in metaphyseal versus diaphyseal cortical bone. J Musculoskelet Neuronal Interact 6(3):258–263PubMed Hamrick MW, Skedros JG, Pennington C, McNeil PL (2006) Increased osteogenic response to exercise in metaphyseal versus diaphyseal cortical bone. J Musculoskelet Neuronal Interact 6(3):258–263PubMed
26.
Zurück zum Zitat Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R (2012) Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27(8):1627–1634. https://doi.org/10.1002/jbmr.1644 CrossRefPubMed Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R (2012) Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27(8):1627–1634. https://​doi.​org/​10.​1002/​jbmr.​1644 CrossRefPubMed
27.
Zurück zum Zitat Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19(8):1259–1269. https://doi.org/10.1359/JBMR.040326 CrossRefPubMed Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19(8):1259–1269. https://​doi.​org/​10.​1359/​JBMR.​040326 CrossRefPubMed
28.
Zurück zum Zitat Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927–2938. https://doi.org/10.1001/jama.296.24.2927 CrossRefPubMed Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927–2938. https://​doi.​org/​10.​1001/​jama.​296.​24.​2927 CrossRefPubMed
29.
Zurück zum Zitat Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM, Group FR (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25(5):976–982. https://doi.org/10.1002/jbmr.11 CrossRefPubMed Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM, Group FR (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25(5):976–982. https://​doi.​org/​10.​1002/​jbmr.​11 CrossRefPubMed
30.
Zurück zum Zitat Merck (2016) Fosamax tablets prescribing information Merck (2016) Fosamax tablets prescribing information
31.
Zurück zum Zitat Bi X, Grafe I, Ding H, Flores R, Munivez E, Jiang MM, Dawson B, Lee B, Ambrose CG (2017) Correlations between bone mechanical properties and bone composition parameters in mouse models of dominant and recessive osteogenesis imperfecta and the response to anti-TGF-beta treatment. J Bone Miner Res 32(2):347–359. https://doi.org/10.1002/jbmr.2997 CrossRefPubMed Bi X, Grafe I, Ding H, Flores R, Munivez E, Jiang MM, Dawson B, Lee B, Ambrose CG (2017) Correlations between bone mechanical properties and bone composition parameters in mouse models of dominant and recessive osteogenesis imperfecta and the response to anti-TGF-beta treatment. J Bone Miner Res 32(2):347–359. https://​doi.​org/​10.​1002/​jbmr.​2997 CrossRefPubMed
33.
Zurück zum Zitat Boskey AL, Donnelly E, Boskey E, Spevak L, Ma Y, Zhang W, Lappe J, Recker RR (2016) Examining the relationships between bone tissue composition, compositional heterogeneity, and fragility fracture: a matched case-controlled FTIRI study. J Bone Miner Res 31(5):1070–1081. https://doi.org/10.1002/jbmr.2759 CrossRefPubMed Boskey AL, Donnelly E, Boskey E, Spevak L, Ma Y, Zhang W, Lappe J, Recker RR (2016) Examining the relationships between bone tissue composition, compositional heterogeneity, and fragility fracture: a matched case-controlled FTIRI study. J Bone Miner Res 31(5):1070–1081. https://​doi.​org/​10.​1002/​jbmr.​2759 CrossRefPubMed
35.
37.
Zurück zum Zitat Martin RB, Burr DB (1989) Structure, function and adaptation of compact bone. Raven Press, New York Martin RB, Burr DB (1989) Structure, function and adaptation of compact bone. Raven Press, New York
40.
Metadaten
Titel
Insights into the bisphosphonate holiday: a preliminary FTIRI study
verfasst von
A. L. Boskey
L. Spevak
Y. Ma
H. Wang
D. C. Bauer
D. M. Black
A. V. Schwartz
Publikationsdatum
05.12.2017
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 3/2018
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-017-4324-5

Weitere Artikel der Ausgabe 3/2018

Osteoporosis International 3/2018 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.